インスリンポンプの世界市場：2025年～2033年

糖尿病および関連疾患の高い有病率が、世界のインスリンポンプ市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予想されます。糖尿病および関連疾患の世界の有病率は差し迫った健康問題となっており、2021年現在、成人人口の約10.5％、約5億3,660万人が糖尿病を患っています。予測によると、この数は2045年までに7億8,300万人にまで増加する可能性があり、効果的な管理戦略を必要とする疫病が拡大していることが明らかになっています。この増加は特に都市部や高所得諸国において顕著であり、そこでは生活習慣が糖尿病発症リスクに大きく寄与しています。

人口の高齢化と、食生活の乱れ、運動不足、肥満率の上昇といったライフスタイルの変化が、糖尿病患者急増の主な要因です。これらの要因は、特に2型糖尿病においてインスリン抵抗性を引き起こし、世界全体の糖尿病患者の約96％を占めています。糖尿病と診断される人の数が増え続けるにつれ、先進的なインスリン送達システムを含む効果的な治療オプションに対する需要が高まっています。

インスリンポンプは、従来の注射法に比べてより正確で柔軟なインスリン送達方法を提供し、糖尿病管理に不可欠なツールとなっています。これらのデバイスは、持続的な皮下インスリン注入を容易にし、血糖値を安定させ、全体的な血糖コントロールを改善するのに役立っています。インスリンポンプの採用が拡大しているのは、患者のQOLを高め、糖尿病管理の日常的負担を軽減する機能が大きく貢献しています。

さらに、業界の主要企業は、この世界のインスリンポンプ市場の成長を促進するであろう製品の承認を得ています。例えば、2023年5月、FDAは6歳以上の1型糖尿病患者を対象としたBeta Bionics iLet ACE PumpおよびiLet Dosing Decision Softwareを承認しました。これらのコンポーネントは、互換性のある持続グルコースモニター（CGM）と併用することで、自動インスリン投与（AID）システムであるiLet Bionic Pancreasを形成します。

また、2023年9月には、Embectaが、1型および2型糖尿病の成人向けに設計されたパッチポンプである使い捨てインスリン送達システムのFDA510（k）認可を取得しました。この"オープンループ"システムは、300ユニットのインスリンリザーバーを備えたチューブレスデザインが特徴です。この設計は、2型糖尿病患者やヘルスケアプロバイダーからのフィードバックに基づいています。最大3日間、調節可能な基礎インスリンとボーラスインスリンを供給します。これらすべての要因が、世界のインスリンポンプ市場に需要をもたらしています。さらに、技術の進歩に対する需要の高まりは、世界のインスリンポンプ市場の拡大に貢献しています。

当レポートでは、世界のインスリンポンプ市場について調査し、市場の概要とともに、タイプ別、製品別、アクセサリ別、適応疾患別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法と範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第5章 戦略的洞察と業界の展望

• 市場のリーダーと先駆者
• 新たな先駆者と著名な参入企業
• 最大の売上を誇るブランドを確立したリーダー
• 確立された製品を持つ市場リーダー
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第6章 タイプ別

• パッチポンプ
• テザーポンプ

第7章 製品別

• MiniMed
• Accu-Chek
• Tandem
• OmniPod
• myLife OmniPod
• その他

第8章 アクセサリ別

• インスリンリザーバーまたはカートリッジ
• インスリンセット挿入器具
• バッテリー

第9章 適応疾患別

• 1型糖尿病
• 2型糖尿病

第10章 エンドユーザー別

• 病院
• 専門クリニック
• 在宅ケア
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他
• 中東・アフリカ

第12章 競合情勢

第13章 企業プロファイル

• Medtronic
• Roche
• Tandem Diabetes Care, Inc.
• Insulet Corporation.
• Ypsomed AG
• Novo Nordisk
• SOOIL Developments Co., Ltd
• Johnson &Johnson Services, Inc.

第14章 付録

The global insulin pump market reached US$ 6.51 billion in 2024 and is expected to reach US$ 13.11 billion by 2033, growing at a CAGR of 8.3 % during the forecast period 2025-2033.

Insulin pumps are small, computerized devices that deliver insulin to people with diabetes via a flexible tube called a catheter, which is inserted under the skin. They offer a continuous, steady flow of insulin (basal) and can also release larger doses (bolus) around mealtime. This delivery method mimics the body's normal release of insulin.

Compared to multiple daily injections, insulin pumps can be more accurate and help to better manage blood sugar levels. They may also reduce the number of needle sticks required and improve A1c levels. Insulin pumps offer more flexibility with diet and exercise and can help manage early morning high blood sugar, also called the "dawn phenomenon".

Insulin pumps can be especially helpful for those who are not meeting blood glucose targets, have gastroparesis, experience nocturnal or frequent low blood sugar levels, or are pregnant. They can also interact with a person's blood glucose monitor to help them understand the patterns of their insulin swings and may be able to automatically adjust insulin levels based on this information. These factors have driven the global insulin pump market expansion.

Market Dynamics: Drivers & Restraints

High Prevalence of Diabetes and Associated Disorders

The high prevalence of diabetes and associated disorders is significantly driving the growth of the global insulin pump market and is expected to drive throughout the market forecast period. The global prevalence of diabetes and related disorders has become a pressing health issue, with approximately 10.5% of the adult population, or around 536.6 million individuals, living with diabetes as of 2021. Projections indicate that this number could escalate to 783 million by 2045, underscoring a growing epidemic that demands effective management strategies. This increase is particularly evident in urban areas and high-income countries, where lifestyle factors significantly contribute to the risk of developing diabetes.

Aging populations, coupled with lifestyle changes such as poor diet, physical inactivity, and rising obesity rates, are primary drivers behind the surge in diabetes cases. These factors lead to insulin resistance, especially in type 2 diabetes, which accounts for about 96% of all diabetes cases globally. As the number of diagnosed individuals continues to rise, there is an increasing demand for effective treatment options, including advanced insulin delivery systems.

Insulin pumps have become essential tools for managing diabetes, offering a more precise and flexible method of insulin delivery compared to traditional injection methods. These devices facilitate continuous subcutaneous insulin infusion, helping to stabilize blood glucose levels and improve overall glycemic control. The growing adoption of insulin pumps is largely driven by their ability to enhance patients' quality of life and reduce the daily burden of diabetes management.

Additionally, key players in the industry product approvals that would drive this global insulin pump market growth. For instance, in May 2023, the FDA cleared the Beta Bionics iLet ACE Pump and iLet Dosing Decision Software for individuals aged six and older with type 1 diabetes. When used with a compatible continuous glucose monitor (CGM), these components form the iLet Bionic Pancreas, an automated insulin delivery (AID) system.

Also, in In September 2023, Embecta, received FDA 510(k) clearance for its disposable insulin delivery system, a patch pump designed for adults with type 1 and type 2 diabetes. This "open-loop" system features a tubeless design with a 300-unit insulin reservoir. The design was based on feedback from people with type 2 diabetes and healthcare providers. It delivers adjustable basal and bolus insulin for up to three days. All these factors demand the global insulin pump market. Moreover, the rising demand for technological advancements contributes to the global insulin pump market expansion.

High Cost of Insulin Pumps

The high cost of insulin pumps is a significant barrier for many individuals managing diabetes. Without insurance, the price of a new insulin pump can reach approximately $6,000, with additional annual costs for supplies ranging from $3,000 to $6,000. These expenses can vary based on the pump's features and the ongoing need for consumables like batteries and sensors. For those without adequate insurance coverage, the financial burden can be overwhelming, as they must also pay separately for the insulin delivered through the device, and a Medtronic insulin pump is currently priced at $8,574.

The high cost of insulin pumps and associated supplies remains a formidable obstacle for many individuals with diabetes, impacting their ability to access essential treatment options and effectively manage their condition. Thus, the above factors could be limiting the global insulin pump market's potential growth.

Segment Analysis

The global insulin pump market is segmented based on type, product, accessories, disease indication, end-user, and region.

Type:

The tethered pumps segment is expected to dominate the global insulin pump market share

The tethered pumps segment holds a major portion of the global insulin pump market share and is expected to continue to hold a significant portion of the global insulin pump market share during the forecast period. Tethered insulin pumps are a significant part of the diabetes management market, providing a more precise and customizable insulin delivery system. These devices use a catheter connected to a pump worn by the user, delivering insulin through an infusion set placed under the skin, typically in the abdomen or thigh.

Tethered pumps allow users to adjust basal rates (background insulin) and bolus doses (mealtime insulin), which can improve blood glucose control, especially for individuals with Type 1 diabetes or Type 2 diabetes who struggle with stable blood sugar levels using traditional injections. Insulin pumps, including tethered pumps, offer significant advantages over traditional insulin therapy by delivering continuous basal insulin and on-demand bolus doses, providing steadier and more consistent insulin flow. This helps users achieve better blood glucose control, reducing A1C levels and minimizing the risk of hypoglycemia.

Additionally, key players in the industry have innovative product launches that would propel this segment's growth in the global insulin pump market. For instance, in December 2023, Tandem Diabetes Care launched updated t: slim X2 insulin pump software in the U.S. that integrates with the Dexcom G7 Continuous Glucose Monitoring (CGM) system4. The t: slim X2 pump, when paired with Control-IQ technology, stands out as the only automated insulin delivery (AID) system that works with Dexcom's G7 CGM. This integration builds upon nearly a decade of collaboration and previous integrations of Dexcom CGM systems. These factors have solidified the segment's position in the global insulin pump market.

Geographical Analysis

North America is expected to hold a significant position in the global insulin pump market share

North America holds a substantial position in the global insulin pump market and is expected to hold most of the market share. The insulin pump market in North America has seen significant growth, driven by the rising prevalence of diabetes, advancements in technology, and increased awareness of insulin pump benefits. This growth is fueled by the increasing number of diabetes cases, especially Type 1 diabetes, and the shift from traditional insulin therapies to more advanced insulin pumps for better glucose control. For instance, in 2021, approximately 38.4 million Americans, representing 11.6% of the population, were living with diabetes. Among these individuals, 29.7 million had received a formal diagnosis, while 8.7 million remained undiagnosed.

Key factors driving the demand for insulin pumps include the growing diabetes epidemic, technological improvements such as integration with continuous glucose monitoring (CGM), and enhanced insurance coverage for these devices. As healthcare spending rises and awareness about diabetes management increases, insulin pumps are becoming more accessible, further boosting market growth.

Additionally, a major of key players' presence, well-advanced healthcare infrastructure, and innovative product launches & approvals would drive this global insulin pump market growth. For instance, in February 2024, Tandem Diabetes Care launched the Tandem Mobi in the U.S., which they claim is the world's smallest durable automated insulin delivery system. With this launch, they are implementing a strategy to provide a diverse range of durable insulin pumps, offering users more choices and innovative options for wearability.

Also, in August 2024, Insulet Corporation announced that its Omnipod 5 Automated Insulin Delivery System is now FDA-cleared for use by adults with type 2 diabetes, aged 18 and older. This marks a significant milestone as the Omnipod 5 becomes the first and only automated insulin delivery (AID) system approved for managing both type 1 and type 2 diabetes. Thus, the above factors are consolidating the region's position as a dominant force in the global insulin pump market.

Asia Pacific is growing at the fastest pace in the global insulin pump market share

Asia Pacific holds the fastest pace in the global insulin pump market and is expected to hold most of the market share. The insulin pump market in the Asia-Pacific (APAC) region has been growing rapidly, driven by a rising diabetic population, increased healthcare investments, and advancements in insulin delivery technology. This growth is largely fueled by the increasing prevalence of diabetes in countries such as China, India, and Japan, alongside a shift towards more advanced diabetes management solutions.

Globally, approximately 1 in 8 adults around 206 million people are living with diabetes. The Western Pacific Region is significantly impacted, accounting for over 38% of the total adult diabetes population. Notably, China alone represents 1 in 4 adults with diabetes worldwide. Alarmingly, more than 53% of these individuals remain undiagnosed.

Diabetes is a major health concern, resulting in 2.3 million deaths in 2021, the highest among all regions reported by the International Diabetes Federation (IDF). The economic burden of diabetes is substantial, with global expenditures reaching USD 241 billion in 2021, which constitutes 25% of total diabetes-related spending. Additionally, about 1 in 7 live births are affected by hyperglycemia during pregnancy, highlighting the widespread impact of this condition on maternal and child health.

Technological advancements, such as continuous glucose monitoring (CGM) integration and user-friendly features, are also making insulin pumps more attractive. Additionally, higher healthcare spending, better insurance coverage, and government initiatives are improving access to insulin pumps, while growing public awareness is expected to further boost market growth in the coming years.

Additionally, key players' strategies such as partnerships & collaborations, and product launches would drive this global insulin pump market growth. For instance, in October 2023, Terumo Corporation and Dexcom, Inc. agreed to end their distribution agreement for Dexcom's Continuous Glucose Monitoring Systems (CGM) in Japan. This decision aligns with Dexcom's new marketing strategy to transition from indirect distribution to direct sales in key markets, excluding the U.S.

Also, in March 2022, Medtronic India launched the MiniMed 780G system, a next-generation closed-loop insulin pump designed for managing type 1 diabetes in individuals aged 7 to 80. This system automates the delivery of both basal insulin and correction boluses every five minutes, helping patients avoid high and low glucose levels with greater ease. The MiniMed 780G system incorporates SmartGuard technology to automatically adjust insulin delivery and correct high glucose levels, while also working to prevent low glucose levels. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global insulin pump market.

Competitive Landscape

The major global players in the insulin Pump market include Medtronic, Roche, Tandem Diabetes Care, Inc., Insulet Corporation., Ypsomed AG, Novo Nordisk, SOOIL Developments Co., Ltd, and Johnson & Johnson Services, Inc. among others.

Key Developments

• In October 2024, Luna Diabetes launched a pivotal trial for its innovative insulin delivery system, known as the Luna, which is touted as the world's smallest insulin patch pump. This system aims to revolutionize nighttime glucose management by delivering micro-doses of insulin while users sleep.
• In September 2024, Modular Medical announced that it had received FDA clearance for its MODD1 insulin pump, which is intended for use by adults with Type 1 and Type 2 diabetes. The company expects to launch the product in early 2025.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global insulin Pump market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Product
• 3.3. Snippet by Accessories
• 3.4. Snippet by Disease Indication
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. High Prevalence of Diabetes and Associated Disorders
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Insulin Pumps
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
• 5.2. Emerging Pioneers and Prominent Players
• 5.3. Established leaders with largest largest-selling Brand
• 5.4. Market leaders with established Product
• 5.5. CXO Perspectives
• 5.6. Latest Developments and Breakthroughs
• 5.7. Case Studies/Ongoing Research
• 5.8. Regulatory and Reimbursement Landscape
• 5.9. North America
• 5.10. Europe
• 5.11. Asia Pacific
• 5.12. Latin America
• 5.13. Middle East & Africa
• 5.14. Porter's Five Force Analysis
• 5.15. Supply Chain Analysis
• 5.16. Patent Analysis
• 5.17. SWOT Analysis
• 5.18. Unmet Needs and Gaps
• 5.19. Recommended Strategies for Market Entry and Expansion
• 5.20. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.21. Pricing Analysis and Price Dynamics
• 5.22. Key Opinion Leaders

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Patch Pumps *
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Tethered Pumps

7. By Product

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.1.2. Market Attractiveness Index, By Product
• 7.2. MiniMed*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Accu-Chek
• 7.4. Tandem
• 7.5. Omnipod
• 7.6. My Life Omnipod
• 7.7. Others

8. By Accessories

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Accessories
  • 8.1.2. Market Attractiveness Index, By Accessories
• 8.2. Insulin Reservoirs or Cartridges*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Insulin Set Insertion Devices
• 8.4. Batteries

9. By Disease Indication

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 9.1.2. Market Attractiveness Index, By Disease Indication
• 9.2. Type 1 Diabetes*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Type 2 Diabetes

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Specialty Clinics
• 10.4. Homecare
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Accessories
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Accessories
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Accessories
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Accessories
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Accessories
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Medtronic*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio
    • 13.1.2.1. Product Description
    • 13.1.2.2. Product Key Performance Indicators (KPIs)
    • 13.1.2.3. Historic and Forecasted Product Sales
    • 13.1.2.4. Product Sales Volume
  • 13.1.3. Financial Overview
    • 13.1.3.1. Company Revenue's
    • 13.1.3.2. Geographical Revenue Shares
    • 13.1.3.3. Revenue Forecasts
  • 13.1.4. Key Developments
    • 13.1.4.1. Mergers & Acquisitions
    • 13.1.4.2. Key Product Development Activities
    • 13.1.4.3. Regulatory Approvals etc.
  • 13.1.5. SWOT Analysis
• 13.2. Roche
• 13.3. Tandem Diabetes Care, Inc.
• 13.4. Insulet Corporation.
• 13.5. Ypsomed AG
• 13.6. Novo Nordisk
• 13.7. SOOIL Developments Co., Ltd
• 13.8. Johnson & Johnson Services, Inc.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us